The company’s current market cap is less than the sum of: 1) cash on hand; and 2) the lump-sum amount that ENTA’s Mavyret royalty stream could garner in a sale to a third party.
In other words, investors are currently ascribing negative value to ENTA’s RSV, HBV, and NASH pipeline!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.